Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade Advances Streamline pillar of Perrigo’s Three-S plan through portfolio…
PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Regulation FD Disclosure. Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade Advances Streamline pillar of Perrigo’s Three-S plan through portfolio simplification Furthers Perrigo’s evolution into a simpler, more focused consumer self-care company Expected to enhance Perri
How this was made
The 30-second read
Why it matters
The agreement provides defined consideration (cash at close plus performance-based contingent payments) and sets expectations for near-term accounting charges, while aiming to improve future margin profile and reduce capital expenditure needs. It also changes how results will be presented (discontinued operations starting Q4 2026).
Market read
Traders can reassess Perrigo’s earnings quality and capital intensity trajectory based on the disclosed impairment, deal economics, and the shift to “Core Perrigo” reporting.
What to watch
Investors may underweight the reporting mechanics change: Infant Formula moves to discontinued operations in Q4 2026, which can materially alter comparability and segment optics even before closing in H1 2027.
Background
Perrigo is executing its “Three-S” plan (Stabilize, Streamline, Strengthen) and is narrowing its portfolio by selling its Infant Formula business.
Ticker impact
Perrigo agreed to divest its Infant Formula business to MeridianMade for up to $175 million, with a $275 to $375 million non-cash impairment expected in Q4 2026.
Likely mixed reaction, with impairment-related concerns near-term but support from clearer “Core Perrigo” earnings profile and reduced future capital expenditure.
The filing discloses both the transaction economics (cash plus contingent milestones) and the expected accounting impact (non-cash impairment range), plus stated strategic benefits (margin profile, reduced capex, discontinued operations reporting).
Market effects
Could shift investor focus within consumer self-care and OTC categories toward “Core” earnings quality and capital intensity, while highlighting infant formula manufacturing outsourcing/contracting dynamics.
Limited direct regional read-through; transaction is between US contract manufacturing and an Irish-domiciled issuer with US-listed shares.
Moderate, as infant nutrition supply chains and contract manufacturing capacity are globally relevant but the disclosure is company-specific.
Counterpoint
The impairment range signals meaningful value write-down risk, so the deal may not be purely value-accretive; contingent milestone structure could also introduce uncertainty into ultimate proceeds.
Key entities
- issuerPerrigo Company plc
NYSE-listed consumer self-care company announcing the divestiture of its Infant Formula business.
- buyerMeridianMade
American contract manufacturing platform dedicated to infant nutrition, acquiring Perrigo’s Infant Formula business.
